PND26 DEMONSTRATING COST-EFFECTIVENESS IN PRIMARY-PROGRESSIVE MULTIPLE SCLEROSIS: CASE STUDY OF A HYPOTHETICAL EMERGING TREATMENT

Value in Health ◽

10.1016/j.jval.2020.04.919 ◽

2020 ◽

Vol 23 ◽

pp. S263

Author(s):

N. Brighton ◽

C. Treharne

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Progressive Multiple Sclerosis ◽

Primary Progressive Multiple Sclerosis ◽

Multiple Sclerosis Case ◽

Primary Progressive

Download Full-text

Cost-Effectiveness Analysis of Alternative Therapies in non-primary progressive Multiple Sclerosis

Research in Social and Administrative Pharmacy ◽

10.1016/j.sapharm.2010.09.006 ◽

2011 ◽

Vol 7 (1) ◽

pp. e1

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Progressive Multiple Sclerosis ◽

Cost Effectiveness Analysis ◽

Alternative Therapies ◽

Primary Progressive Multiple Sclerosis ◽

Primary Progressive ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness of Interferon Beta-1a, Interferon Beta-1b, and Glatiramer Acetate in Newly Diagnosed Non-primary Progressive Multiple Sclerosis

Value in Health ◽

10.1111/j.1524-4733.2004.75007.x ◽

2004 ◽

Vol 7 (5) ◽

pp. 554-568 ◽

Author(s):

Lisa A. Prosser ◽

Karen M. Kuntz ◽

Amit Bar-Or ◽

Milton C. Weinstein

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Progressive Multiple Sclerosis ◽

Primary Progressive Multiple Sclerosis ◽

Newly Diagnosed ◽

Primary Progressive

Download Full-text

Projecting the Potential Cost Effectiveness of Ocrelizumab Versus Standard Care in Primary Progressive Multiple Sclerosis Patients Under Alternative Pricing Scenarios

Value in Health ◽

10.1016/j.jval.2016.03.200 ◽

2016 ◽

Vol 19 (3) ◽

pp. A62-A63

Author(s):

K Suh ◽

JJ Carlson ◽

LP Garrison

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Standard Care ◽

Progressive Multiple Sclerosis ◽

Primary Progressive Multiple Sclerosis ◽

Potential Cost ◽

Primary Progressive ◽

Multiple Sclerosis Patients

Download Full-text

Searching for early CSF biomarkers of primary progressive multiple sclerosis

10.26226/morressier.5b719e465aff74008ae4cb58 ◽

2018 ◽

Author(s):

Damiano Marastoni ◽

Roberta Magliozzi

Keyword(s):

Multiple Sclerosis ◽

Progressive Multiple Sclerosis ◽

Csf Biomarkers ◽

Primary Progressive Multiple Sclerosis ◽

Primary Progressive

Download Full-text

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Case Medical Research ◽

10.31525/ct1-nct04035005 ◽

2019 ◽

Author(s):

Keyword(s):

Multiple Sclerosis ◽

Progressive Multiple Sclerosis ◽

Primary Progressive Multiple Sclerosis ◽

Efficacy And Safety ◽

Primary Progressive

Download Full-text

Faculty Opinions recommendation of Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717955622.793460622 ◽

2012 ◽

Author(s):

Monica Marta

Keyword(s):

Multiple Sclerosis ◽

Progressive Multiple Sclerosis ◽

Primary Progressive Multiple Sclerosis ◽

Primary Progressive ◽

Meningeal Inflammation

Download Full-text

Faculty Opinions recommendation of Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718018944.793478763 ◽

2013 ◽

Author(s):

Marco Rovaris

Keyword(s):

Multiple Sclerosis ◽

Progressive Multiple Sclerosis ◽

Primary Progressive Multiple Sclerosis ◽

Disease Course ◽

Primary Progressive

Download Full-text

Gray Matter Atrophy in the Cortico-Striatal-Thalamic Network and Sensorimotor Network in Relapsing–Remitting and Primary Progressive Multiple Sclerosis

Neuropsychology Review ◽

10.1007/s11065-021-09479-3 ◽

2021 ◽

Author(s):

Yuan Cao ◽

Wei Diao ◽

Fangfang Tian ◽

Feifei Zhang ◽

Laichang He ◽

...

Keyword(s):

Multiple Sclerosis ◽

Gray Matter ◽

Progressive Multiple Sclerosis ◽

Primary Progressive Multiple Sclerosis ◽

Sensorimotor Network ◽

Primary Progressive ◽

Gray Matter Atrophy ◽

Relapsing Remitting

Download Full-text

Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression

Journal of Medical Economics ◽

10.1080/13696998.2021.1872585 ◽

2021 ◽

Vol 24 (1) ◽

pp. 140-149

Author(s):

Laurie J. Brown ◽

Jinjing Li ◽

Matthias Brunner ◽

Martin Snoke ◽

Hai A. La

Keyword(s):

Multiple Sclerosis ◽

Economic Impact ◽

Disease Progression ◽

Progressive Multiple Sclerosis ◽

Primary Progressive Multiple Sclerosis ◽

Societal Costs ◽

Primary Progressive ◽

Delay Disease Progression ◽

Disease Modifying ◽

Disease Modifying Treatment

Download Full-text

Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study)

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2021.102860 ◽

2021 ◽

Vol 50 ◽

pp. 102860 ◽

Author(s):

Francisco Pérez-Miralles ◽

Daniel Prefasi ◽

Antonio García-Merino ◽

José Ramón Ara ◽

Guillermo Izquierdo ◽

...

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Employment Outcomes ◽

Progressive Multiple Sclerosis ◽

Primary Progressive Multiple Sclerosis ◽

Primary Progressive ◽

Download Full-text